Talazoparib Pfizer

Talazoparib (Talazoparib), developed by Pfizer of the United States, is an oral poly ADP-ribose polymerase (PARP) inhibitor that plays a role in DNA damage repair. Preclinical studies have shown that talazopanib blocks the activity of the PARP enzyme and captures PARP at sites of DNA damage, leading to reduced cancer cell growth and cancer cell death. Patients need to be selected for treatment based on a U.S. Food and Drug Administration (FDA)-approved companion diagnostic for talazopanib.

Talazopanib is approved in more than 70 countries, including the United States, as once-daily monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer. Recently, Pfizer demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) with talazopanib plus enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations, based on positive results from the TALAPRO-2 study.

The original drug of talazopanib has not yet been marketed in China, so it has not been included in medical insurance. The original drug specification of talazopanib listed overseas is 0.25mg*30 capsules, and the price per box may be around RMB 10,000 (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheaper generics of talazopanib overseas. For example, the price of a box of 1mg*30 pills produced by a Laos pharmaceutical factory may be more than 3,000 yuan (the price may fluctuate due to the exchange rate).